Division of Cancer Treatment and Diagnosis (DCTD)
Home | Sitemap | Contact DCTD
Cancer Therapy Evaluation Program (CTEP)
Overview
Major Ongoing Initiatives
Significant Ongoing Clinical Trials
Current Funding Opportunities
Partnerships and Collaborations
Scientific Advances
Tools, Products, and Resources

DCTD Programs

  • Cancer Diagnosis Program
  • Cancer Imaging Program
  • Cancer Therapy Evaluation Program
  • Developmental Therapeutics Program
  • Radiation Research Program
  • Biometric Research Branch
  • Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/06/07
For More Details
about CTEP
CTEP Home Page
Visit the CTEP Website

CTEP Significant Ongoing Clinical Trials

  • A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
  • A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
  • Phase II Pilot Trial of Sorafenib Plus Interferon Alpha-2b in Metastatic Renal Cell Cancer
  • Targeted Therapy Combinations in Glioma, Melanoma, and Renal Cell Cancer
DCTD Home | Text-onlyText and Graphics | Contact DCTD | Site Map | NCI Home | Policies
National Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov